REGENERON PHARMACEUTICALS, INC. Quarterly Income Tax Expense (Benefit) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Regeneron Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q3 2024.
  • Regeneron Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $152M, a 48% increase year-over-year.
  • Regeneron Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $315M, a 18.3% decline year-over-year.
  • Regeneron Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $246M, a 52.8% decline from 2022.
  • Regeneron Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $520M, a 58.4% decline from 2021.
  • Regeneron Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $1.25B, a 321% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $315M $152M +$49.4M +48% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $266M $196M +$81.3M +71% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $184M -$21.3M -$61.5M -153% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $246M -$12M -$140M -109% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-05
Q3 2023 $385M $103M -$91.1M -46.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $476M $115M +$3.4M +3.06% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $473M $40.2M -$47.4M -54.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $520M $128M -$147M -53.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-05
Q3 2022 $667M $194M +$9.7M +5.26% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $658M $111M -$543M -83% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $1.2B $87.6M -$50.2M -36.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $1.25B $274M +$199M +264% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-05
Q3 2021 $1.05B $184M +$28.2M +18.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $1.02B $654M +$632M +2927% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $391M $138M +$93.8M +213% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $297M $75.4M -$22.4M -22.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-06
Q3 2020 $320M $156M +$57.3M +57.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $262M $21.6M -$10M -31.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $272M $44M -$41M -48.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $313M $97.8M +$242M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-07
Q3 2019 $71.3M $98.9M +$57.7M +140% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $13.6M $31.6M -$73.1M -69.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $86.7M $85M -$22.4M -20.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $109M -$144M -$525M -138% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-08
Q3 2018 $635M $41.2M -$136M -76.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $771M $105M -$33.4M -24.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $804M $107M -$76M -41.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $880M $381M +$293M +331% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-07
Q3 2017 $587M $177M +$76.2M +75.4% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $511M $138M +$42.1M +43.8% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $469M $183M +$34.6M +23.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $434M $88.4M +$16.1M +22.3% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-07
Q3 2016 $418M $101M -$81.8M -44.7% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $500M $96M -$37.3M -28% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $537M $149M -$51.7M -25.8% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $589M $72.3M -$27.3M -27.4% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-08
Q3 2015 $616M $183M +$84.4M +85.8% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 $532M $133M +$20.9M +18.6% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 $511M $201M +$87.9M +78.1% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q4 2014 $423M $99.6M +$4.64M +4.88% Oct 1, 2014 Dec 31, 2014 10-Q 2015-11-04
Q3 2014 $418M $98.4M +$14.1M +16.7% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-04
Q2 2014 $404M $112M +$52.1M +86.4% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-04
Q1 2014 $352M $113M +$69.6M +162% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q4 2013 $283M $95M +$431M Oct 1, 2013 Dec 31, 2013 10-K 2016-02-11
Q3 2013 -$148M $84.4M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-04
Q2 2013 $60.3M +$60.3M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-05
Q1 2013 $43M Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-08
Q4 2012 -$336M -$335M -54502% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-13
Q2 2012 $0 +$863K Apr 1, 2012 Jun 30, 2012 10-Q 2012-07-25
Q4 2011 -$1.13M -$615K -$615K Oct 1, 2011 Dec 31, 2011 10-K 2014-02-13
Q3 2011 -$517K $562K +$562K Jul 1, 2011 Sep 30, 2011 10-Q 2012-10-24
Q2 2011 -$1.08M -$863K -$863K Apr 1, 2011 Jun 30, 2011 10-Q 2012-07-25
Q1 2011 -$216K -$216K* -$216K Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-26
Q4 2010 $0 $0 Oct 1, 2010 Dec 31, 2010 10-K 2012-02-21
Q3 2010 $0 Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-27
Q2 2010 $0 Apr 1, 2010 Jun 30, 2010 10-Q 2011-07-28
Q1 2010 $0 Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.